Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Molecular Pathology of Lung Cancer: Current Status and Future Directions

  • Roh, Mee Sook (Department of Pathology, Dong-A University College of Medicine)
  • Received : 2014.06.21
  • Accepted : 2014.07.04
  • Published : 2014.08.29
Download PDF
⟨ Previous Next ⟩

Abstract

The rapid development of targeted therapies has enormously changed the clinical management of lung cancer patients over the past decade; therefore, molecular testing, such as epidermal growth factor receptor (EGFR) gene mutations or anaplastic lymphoma kinase (ALK) gene rearrangements, is now routinely used to predict the therapeutic responses in lung cancer patients. Moreover, as technology and knowledge supporting molecular testing is rapidly evolving, the landscape of targetable genomic alterations in lung cancer is expanding as well. This article will summarize the current state of the most commonly altered and most clinically relevant genes in lung cancer along with a brief review of potential future developments in molecular testing of lung cancer.

Keywords

References

  1. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8: 823-59. https://doi.org/10.1097/JTO.0b013e318290868f
  2. Thunnissen E, van der Oord K, den Bakker M. Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch 2014;464:347-58. https://doi.org/10.1007/s00428-014-1535-4
  3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-39. https://doi.org/10.1056/NEJMoa040938
  4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. https://doi.org/10.1056/NEJMoa0810699
  5. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34. https://doi.org/10.1200/JCO.2012.44.2806
  6. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. https://doi.org/10.1038/nature05945
  7. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94. https://doi.org/10.1056/NEJMoa1214886
  8. Dacic S, Nikiforova MN. Present and future molecular testing of lung carcinoma. Adv Anat Pathol 2014;21:94-9. https://doi.org/10.1097/PAP.0000000000000012
  9. Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol 2014;232:121-33. https://doi.org/10.1002/path.4275
  10. Cagle PT, Allen TC, Olsen RJ. Lung cancer biomarkers: present status and future developments. Arch Pathol Lab Med 2013;137:1191-8. https://doi.org/10.5858/arpa.2013-0319-CR
  11. Cooper WA, Lam DC, O'Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis 2013;5 Suppl 5:S479-90.
  12. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008; 456:53-9. https://doi.org/10.1038/nature07517
  13. Summerer D. Enabling technologies of genomic-scale sequence enrichment for targeted high-throughput sequencing. Genomics 2009;94:363-8. https://doi.org/10.1016/j.ygeno.2009.08.012
  14. Glenn TC. Field guide to next-generation DNA sequencers. Mol Ecol Resour 2011;11:759-69. https://doi.org/10.1111/j.1755-0998.2011.03024.x
  15. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11-31. https://doi.org/10.1677/erc.0.0080011
  16. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013;24: 2371-6. https://doi.org/10.1093/annonc/mdt205
  17. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73. https://doi.org/10.1371/journal.pmed.0020073
  18. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALKpositive lung cancer. Clin Cancer Res 2009;15:3143-9. https://doi.org/10.1158/1078-0432.CCR-08-3248
  19. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, Mc-Donald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70. https://doi.org/10.1200/JCO.2011.35.6345
  20. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-7. https://doi.org/10.1038/nm.2644
  21. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29:3574-9. https://doi.org/10.1200/JCO.2011.35.9638
  22. Sadiq AA, Salgia R. MET as a possible target for non-smallcell lung cancer. J Clin Oncol 2013;31:1089-96. https://doi.org/10.1200/JCO.2012.43.9422
  23. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43. https://doi.org/10.1126/science.1141478
  24. Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013;31:1997-2003. https://doi.org/10.1200/JCO.2012.45.6095
  25. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011;6:e20351. https://doi.org/10.1371/journal.pone.0020351
  26. Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 2012;18:6771-83. https://doi.org/10.1158/1078-0432.CCR-12-2347
  27. Abdulkareem IH, Blair M. Phosphatase and tensin homologue deleted on chromosome 10. Niger Med J 2013;54:79-86. https://doi.org/10.4103/0300-1652.110033
  28. Takeda H, Takigawa N, Ohashi K, Minami D, Kataoka I, Ichihara E, et al. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res 2013;319:417-23. https://doi.org/10.1016/j.yexcr.2012.12.018
  29. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1:78-89. https://doi.org/10.1158/2159-8274.CD-11-0005
  30. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85. https://doi.org/10.1097/JTO.0b013e318206a221
  31. Shim HS, Chung JH, Kim L, Chang S, Kim WS, Lee GK, et al. Guideline recommendations for EGFR mutation testing in lung cancer: proposal of the Korean Cardiopulmonary Pathology Study Group. Korean J Pathol 2013;47:100-6. https://doi.org/10.4132/KoreanJPathol.2013.47.2.100
  32. Kim H, Shim HS, Kim L, Kim TJ, Kwon KY, Lee GK, et al. Guideline recommendations for testing of ALK gene rearrangement in lung cancer: a proposal of the Korean Cardiopulmonary Pathology Study Group. Korean J Pathol 2014;48: 1-9. https://doi.org/10.4132/KoreanJPathol.2014.48.1.1
  33. Thomas A, Rajan A, Lopez-Chavez A, Wang Y, Giaccone G. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol 2013;24:577-85. https://doi.org/10.1093/annonc/mds478
  34. Persson K, Hamby K, Ugozzoli LA. Four-color multiplex reverse transcription polymerase chain reaction--overcoming its limitations. Anal Biochem 2005;344:33-42. https://doi.org/10.1016/j.ab.2005.06.026
  35. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013;45:1113-20. https://doi.org/10.1038/ng.2764
  36. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150: 1107-20. https://doi.org/10.1016/j.cell.2012.08.029
  37. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25. https://doi.org/10.1038/nature11404

Cited by

  1. Upregulation of SOX9 promotes cell proliferation, migration and invasion in lung adenocarcinoma vol.10, pp.2, 2015, https://doi.org/10.3892/ol.2015.3303
  2. Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival vol.5, pp.None, 2014, https://doi.org/10.1038/srep16889
  3. Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry vol.82, pp.2, 2014, https://doi.org/10.4046/trd.2017.0128
  4. High NF-E2-related factor 2 expression predicts poor prognosis in patients with lung cancer: a meta-analysis of cohort studies vol.54, pp.11, 2020, https://doi.org/10.1080/10715762.2019.1642472
  5. Prevalence of Targetable Mutations in Black Patients With Lung Cancer: A Systematic Review and Meta-Analysis vol.17, pp.5, 2021, https://doi.org/10.1200/op.20.00961